Presence and Impact of Fatigue in Patients With Multiple Sclerosis.

Authors

Meheroz H Rabadi, Kimberly A Russell, Chao Xu

Published in

Medical science monitor : international medical journal of experimental and clinical research. Volume 32. Pages e953344. Jul 07, 2026. Epub Jul 07, 2026.

Abstract

BACKGROUND Fatigue is common in multiple sclerosis (MS) and adversely affects function and quality of life. We examined clinical correlates of fatigue, its relationship with depression and sleepiness, and whether fatigue-related medications improve patient-reported outcomes. MATERIAL AND METHODS This single-center, longitudinal observational study retrospectively analyzed prospectively collected data from 203 veterans, categorized based on the presence or absence of fatigue. Primary outcomes were changes in the Fatigue Severity Scale (FSS), Modified Fatigue Impact Scale (MFIS), and Epworth Sleepiness Scale (ESS) from baseline to 12 months. Secondary outcomes included changes in the EuroQol 5-Dimension Questionnaire (EQ-5D), EQ visual analog scale (EQ-VAS), Total Functional Independence Measure (TFIM), Expanded Disability Status Scale (EDSS), 2-Minute Walk Test (2MWT), and Beck Depression Inventory (BDI). Medication exposure (amantadine, modafinil/armodafinil, methylphenidate/dextroamphetamine) was recorded. RESULTS Fatigue was present in 134 of 203 (66%) and associated with higher body mass index (30.1±5.5), hyperlipidemia (53.7%), diabetes (16.4%), higher BDI (4.58±4.36) and ESS (10.7±6.51), and worse EQ-5D VAS (all P<0.01). Strong positive correlations were observed among fatigue (FSS/MFIS), depression (BDI), sleepiness (ESS), and disability (EDSS) scales (P<0.05). Compared with no medication, fatigue-related medications did not improve FSS/MFIS or EQ-VAS scores; however, modest gains favored treated patients in TFIM change (P=0.04) and 2MWT distance (P=0.02). Post hoc comparisons across amantadine, modafinil/armodafinil, and amphetamine showed no between-drug differences in primary or secondary outcomes. CONCLUSIONS MS fatigue in veterans is highly prevalent and closely linked to metabolic comorbidities, depression, and sleep disturbance. Common fatigue medications provided no improvement in fatigue severity and quality of life.

PMID:
42410895
Bibliographic data and abstract were imported from PubMed on 07 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.